Dudley Benjafield

Even 2 Hours of PAP Therapy per Night Benefits Sleep Apnea Sufferers: ResMed Study

Retrieved on: 
Wednesday, May 18, 2022
Risk, Medicaid, ResMed, Conditional sentence, International Conference on Population and Development, Critical care, Sleep apnea, Hospital, COPD, Insurance, Solution, Patient, Quality of life, Sleep medicine, ASX, University of California, San Diego, PAP, Caregiver, Research, Medicare, Observational study, SAN, Conference, RMD, University, Dudley Benjafield, Centers for Medicare & Medicaid Services, Center, American Thoracic Society, GLOBE, NYSE, Sleep, Fireworks, Silviculture, Pharmaceutical industry, Health insurance, Wood drying

Benefits were seen at 90 days, one year, and two years into the study.

Key Points: 
  • Benefits were seen at 90 days, one year, and two years into the study.
  • An estimated 54 million Americans have obstructive sleep apnea,3 a chronic disease in which throat muscles relax during sleep, constricting airflow.
  • The bodys resulting jolt awake to take a breath causes dozens to hundreds of sleep interruptions per night.
  • Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases.

ResMed’s Global Sleep Surveys Reveal What’s Keeping Us Up at Night; Aim to Bring Awareness to the State of Sleep Health for World Sleep Day

Retrieved on: 
Monday, March 14, 2022
People, Sleep apnea, National Sleep Foundation, Snoring, Risk, Apnea, Sleep, Quality of life, Conditional sentence, Depression, RMD, Self-assessment, Dudley Benjafield, ResMed, NYSE, GLOBE, Mental health, Solution, COPD, ASX, Anxiety, Caregiver, Awareness, SAN, Online shopping, Online gambling, Medicine, Pharmaceutical industry

In the United States, 38% of respondents cited depression and anxiety as the reasons they do not sleep well at night.

Key Points: 
  • In the United States, 38% of respondents cited depression and anxiety as the reasons they do not sleep well at night.
  • Beyond stress, depression, and anxiety, respondents listed family pressures, work-related concerns, and financial pressures as reasons for not sleeping well.
  • The survey also revealed how returning to the office has impacted the way people believe their sleep quality will change.
  • To learn more about the state of sleep health across the globe and sleep apnea, or to take a quick self-assessment for your risk of sleep apnea, visit SleepForBetterTomorrow.com .

Signifier Medical Technologies is Granted HCPCS Codes for eXciteOSA to Help Patients Access Innovative Technology

Retrieved on: 
Tuesday, February 22, 2022
Biotechnology, Mental Health, Medical Devices, Health, Pharmaceutical, Diabetes, Center, Stroke, Obstructive sleep apnea, McNicholas, OSA, Hypertension, Literature review, Solution, Incidence, Snoring, Depression, The New England Journal of Medicine, Centers for Medicare & Medicaid Services, Hypopnea, Veni, vidi, vici, Man, Sleep apnea, LLC, Multimedia, Kotecha, Maintenance, Quality of life, DME, Population health, Medicare, Population, HCPCS, Moyamoya disease, NMES, Heart failure, Continuous positive airway pressure, Observational study, TIA, Sleep, Patient, Signified and signifier, CMS, Health, Physician, Death, Association, Sleep-related breathing disorder, PubMed, Meta-analysis, Electricity, Ageing, JAMA Internal Medicine, News, FDA, Lancet, Health technology, Cardiovascular disease, Medical device, Hospital, Pharmaceutical industry, Wood drying, Silviculture, Dudley Benjafield, Signifier Medical Technologies, eXciteOSA®, Snoring and Obstructive Sleep Apnea, SIGNIFIER MEDICAL TECHNOLOGIES, EXCITEOSA®, SNORING AND OBSTRUCTIVE SLEEP APNEA

We welcome CMS decision to establish two new codes to describe the eXciteOSA device, said Akhil Tripathi, Chief Executive Officer at Signifier.

Key Points: 
  • We welcome CMS decision to establish two new codes to describe the eXciteOSA device, said Akhil Tripathi, Chief Executive Officer at Signifier.
  • HCPCS codes play a critical role in providing patients with access to new medical devices, often improving payment options and healthcare decisions, said Dr. Marc Benton, a New Jersey-based pulmonologist and sleep medicine specialist.
  • The eXciteOSA is a non-invasive, easy to use therapy that does not require patients to wear any sort of device during the night.
  • Unlike other devices which are used while patients sleep, eXciteOSA is the first commercially available device used while awake.

ResMed Launches AirSense 11 PAP Series, Advancing Digital Health in Sleep Apnea Treatment

Retrieved on: 
Monday, August 16, 2021
Time, Caregiver, Obstructive sleep apnea, Personal, APAP, NYSE, Conditional sentence, SAN, Dudley Benjafield, MyAir, GLOBE, ASX, Patient, Algorithm, PAP, Smartphone, COPD, CPAP, Sleep apnea, Quality of life, RMD, Pharmaceutical industry, Medical device, Hospital

AirSense 11s new tailored features along with our myAir patient engagement app help give people the support they need to use PAP the gold standard for treating sleep apnea comfortably and confidently every night, said Jim Hollingshead, ResMed president of Sleep and Respiratory Care.

Key Points: 
  • AirSense 11s new tailored features along with our myAir patient engagement app help give people the support they need to use PAP the gold standard for treating sleep apnea comfortably and confidently every night, said Jim Hollingshead, ResMed president of Sleep and Respiratory Care.
  • And when digital health helps guide patients, it enables clinicians to provide great care to all their patients more efficiently.
  • AirSense 11 is available in the U.S., with other countries to follow, and is compatible with all ResMed masks.
  • Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases.